'Trastuzumab' presentation slideshows

Monday Night with Research To Practice: An 8-Part Live CME Webcast Series

Monday Night with Research To Practice: An 8-Part Live CME Webcast Series. Part VI: HER2-Positive Gastric Cancer Monday, October 25, 2010 7:30 PM - 8:30 PM ET. Jaffer A Ajani, MD Professor of Medicine Department of Gastrointestinal Medical Oncology

1.02k views • 78 slides

Marco Venturini (1954-2011)

734 views • 73 slides

2 nd annual San Antonio breast cancer symposium review january 28, 2012

2 nd annual San Antonio breast cancer symposium review january 28, 2012. Sponsored By:. SABCS 2011 Review: HER2-Directed Therapy in Breast Cancer. Chau Dang, MD Assistant Professor of Medicine Weill Cornell Medical College Breast Cancer Medicine Service

887 views • 66 slides

Moderator Neil Love, MD

739 views • 62 slides

728 views • 51 slides

692 views • 51 slides

Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms

Adjuvant Breast Cancer Therapy An Analysis of Current Treatment Paradigms. Mark D. Pegram, MD UCLA/Jonsson Comprehensive Cancer Center. Age 47 Premenopausal breast carcinoma Lumpectomy - 1.3 cm poorly differentiated, high grade infiltrating ductal carcinoma

824 views • 41 slides

Pr Thierry PETIT - Centre Paul Strauss

Combinaisons ou séquences de traitement/traitements multicibles Point de vue du clinicien. Pr Thierry PETIT - Centre Paul Strauss. Traitements multicibles. En phase métastatique. Hormonothérapie et thérapies ciblées. 1. Moy B et al. Clin Cancer Res . 2006;12:4790-4793.

691 views • 40 slides

Key Issues in the Management of Metastatic Breast Cancer

Case 2 (HER2 positive), v5 - July 3, 2009 - to Abraxis Medical. Key Issues in the Management of Metastatic Breast Cancer. Case. First-Line Treatment of HER2-Positive ER-Negative Metastatic Breast Cancer. Case: History. 47-year-old woman with invasive ductal carcinoma 2.0 cm Node negative

590 views • 40 slides

Terapia Neoadiuvante Revisione delle evidenze scientifiche

Terapia Neoadiuvante Revisione delle evidenze scientifiche. Valentina Guarneri Nonantola, 19 Novembre 2011. Preoperative vs postoperative, Overall Survival. DDFS o OS???. The Cochrane Library, Issue 3, 2008. pCR vs residual disease, Overall Survival. The Cochrane Library, Issue 3, 2008.

415 views • 27 slides

Highlights in the Management of Breast Cancer Rome, May 25-26, 2007

396 views • 26 slides

ADJUVANT TREATMENT: TARGET THERAPIES

BELGIAN BREAST MEETING 13-14 October 2006 Brussels, Belgium. ADJUVANT TREATMENT: TARGET THERAPIES. Fatima Cardoso, MD Jules Bordet Institute & TRANSBIG. ENDOCRINE THERAPY First example of TARGETED THERAPY. Aromatase inhibitors. ER. The target. The ligand. SERMS & ER DOWN REGULATORS.

382 views • 24 slides

Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer

Updates from the San Antonio Breast Cancer Symposium 2013 HER2+ Breast Cancer. Julie R. Gralow, M.D. Director and Jill Bennett Professor of Breast Medical Oncology Professor of Global Health University of Washington School of Medicine Fred Hutchinson Cancer Research Center

932 views • 22 slides

Schema di chemioterapia da associare a trastuzumab e valutazione della risposta

359 views • 22 slides

Carcinoma mammario metastatico CASO CLINICO n.2

Carcinoma mammario metastatico CASO CLINICO n.2. Stefania Gori Oncologia Medica- Perugia. Caso clinico n.2. Agosto 2009: Donna di anni 37 anni, premenopausa, operata altrove di quadrantectomia mammaria Sx + dissezione ascellare per ca. duttale infiltrante

374 views • 18 slides

Goldhirsch A et al. Proc SABCS 2012;Abstract S5-2.

HERA TRIAL: 2 Years versus 1 Year of Trastuzumab After Adjuvant Chemotherapy in Women with HER2-Positive Early Breast Cancer at 8 Years of Median Follow-Up. Goldhirsch A et al. Proc SABCS 2012;Abstract S5-2. Background.

265 views • 10 slides

Untch M et al. Proc SABCS 2010 ; Abstract S3-1.

Lapatinib versus Trastuzumab in Combination with Neoadjuvant Anthracycline-Taxane-Based Chemotherapy: Primary Efficacy Endpoint Analysis of the GEPARQUINTO Study (GBG 44). Untch M et al. Proc SABCS 2010 ; Abstract S3-1. Objectives. Primary: Pathological CR rates Secondary:

203 views • 9 slides

Datko F et al. Proc SABCS 2012; Abstract P5-18- 20.

A Phase II Study of Pertuzumab , Trastuzumab , and Weekly Paclitaxel in Patients with HER2 - Overexpressing Metastatic Breast Cancer. Datko F et al. Proc SABCS 2012; Abstract P5-18- 20. Background.

311 views • 9 slides

BCIRG 007 Metastatic Breast Cancer First Line

BCIRG 007 Metastatic Breast Cancer First Line. TH Docetaxel 100 mg/m 2. HER2 + FISH. Trastuzumab until progression. TCH Docetaxel 75 mg/m 2 and Carboplatin. N=444. AUC 6. Trastuzumab until progression.

153 views • 1 slides

BCIRG 007 Metastatic Breast Cancer First Line

BCIRG 007 Metastatic Breast Cancer First Line. TH Docetaxel 100 mg/m 2. HER2 + FISH. Trastuzumab until progression. TCH Docetaxel 75 mg/m 2 and Carboplatin. N=444. AUC 6. Trastuzumab until progression.

134 views • 1 slides